Last reviewed · How we verify

Clindamycin Phosphate / Benzoyl Peroxide Gel

Watson Laboratories, Inc. · Phase 3 active Small molecule

Clindamycin reduces acne-causing bacteria while benzoyl peroxide provides antimicrobial and keratolytic effects to treat acne vulgaris.

Clindamycin reduces acne-causing bacteria while benzoyl peroxide provides antimicrobial and keratolytic effects to treat acne vulgaris. Used for Acne vulgaris.

At a glance

Generic nameClindamycin Phosphate / Benzoyl Peroxide Gel
Also known asGeneric
SponsorWatson Laboratories, Inc.
Drug classTopical antibiotic combination
TargetBacterial ribosome (clindamycin); oxidative antimicrobial mechanism (benzoyl peroxide)
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis, reducing Cutibacterium acnes (formerly Propionibacterium acnes) colonization. Benzoyl peroxide acts as an oxidizing agent with broad antimicrobial activity and helps normalize keratinization. The combination provides synergistic antibacterial effects while reducing the risk of antibiotic resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: